+46.6%
ASML vs MRNA
+986.9%
-940.3%
-31.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +6.2% | +5.8% | +0.4% | +6.1% |
| 7D | -0.8% | +21.8% | -22.7% | -1.0% |
| 30D | -14.9% | +19.6% | -34.4% | -15.0% |
| 3M | -13.0% | +354.6% | -367.6% | -14.9% |
| 6M | -4.7% | +394.9% | -399.6% | -10.3% |
| YTD | +42.3% | +812.2% | -769.9% | +24.9% |
| All | +46.6% | +986.9% | -940.3% | +26.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling